Details for Patent: 8,809,322
✉ Email this page to a colleague
Which drugs does patent 8,809,322 protect, and when does it expire?
Patent 8,809,322 protects NAYZILAM and is included in one NDA.
Summary for Patent: 8,809,322
| Title: | Methods and compositions for the delivery of a therapeutic agent |
| Abstract: | The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal. |
| Inventor(s): | Gizurarson; Sveinbjorn (Reykjavik, IS) |
| Assignee: | Hananja EHF (Reykjavik, IS) University of Iceland (Reykjavik, IS) |
| Application Number: | 13/446,284 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,809,322 |
|
Patent Claim Types: see list of patent claims | Composition; |
Drugs Protected by US Patent 8,809,322
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucb Inc | NAYZILAM | midazolam | SPRAY;NASAL | 211321-001 | May 17, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,809,322
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Iceland | 85932007 | Jan 19, 2007 |
